Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Itälä-Remes, Maija  [Clear All Filters]
2024
Nihtilä J, Salmenniemi U, Itälä-Remes M, Crossland RE, Gallardo D, Bogunia-Kubik K, Łacina P, Bieniaszewska M, Giebel S, Hyvärinen K, et al. Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort. Hum Immunol. 2024:110791.
Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, Itälä-Remes M, Corral LLopez, Schaap NPM, Karas M, et al. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12(1).
Averbuch D, Tridello G, Wendel L, Itälä-Remes M, Oren I, Karas M, Blijlevens N, Beguin Y, Broers A, Calore E, et al. Listeria monocytogenes infections in hematopoietic cell transplant recipients: clinical manifestations and risk factors: A multinational retrospective case control study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and. Transplant Cell Ther. 2024.
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Remenyi PPal, Versluis J, Rovira M, Blaise D, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT. Blood. 2024.
2023
Fein JAlexander, Shouval R, Galimard J-E, Labopin M, Socié G, Finke J, Cornelissen JJ, Malladi R, Itälä-Remes M, Chevallier P, et al. Comorbidities in recipients of low transplant conditioning intensity regimens for acute myeloid leukemia: an ALWP EBMT study. Blood Adv. 2023.
Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itälä-Remes M, Zuckerman T, Beguin Y, Schaap N, et al. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2023.
Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023.
Dalle IAbou, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, et al. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023.
Gagelmann N, Eikema D-J, Koster L, Netelenbos T, McDonald A, Stoppa A-M, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, et al. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. Eur J Haematol. 2023.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of th. Hemasphere. 2023;7(7):e920.
2020
Piñana JLuis, Xhaard A, Tridello G, Passweg J, Kozijn A, Polverelli N, Heras I, Pérez A, Sanz J, Berghuis D, et al. Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2020.
2019
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Gagelmann N, Eikema D-J, Koster L, Caillot D, Pioltelli P, Lleonart JBargay, Reményi P, Blaise D, Schaap N, Trneny M, et al. Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2019.
2018
Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, et al. Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. Am J Hematol. 2018.
Ranti J, Kurki S, Salmenniemi U, Putkonen M, Salomäki S, Itälä-Remes M. Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT. PLoS One. 2018;13(9):e0204136.
Clancy J, Ritari J, Lobier M, Niittyvuopio R, Salmenniemi U, Putkonen M, Itälä-Remes M, Partanen J, Koskela S. Increased MHC matching by C4 gene compatibility in URD HSCT. Biol Blood Marrow Transplant. 2018.
2016
Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016.